MedTrace Logo

Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

NCT00168181 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2011-04-18

No results posted yet for this study

Summary

This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.

Conditions

Interventions

PROCEDURE

Submandibular gland Transfer

DRUG

Salagen

Sponsors & Collaborators

  • CancerCare Manitoba

    collaborator OTHER

  • Jewish General Hospital

    collaborator OTHER

  • Newfoundland Cancer Treatment & Research Foundation

    collaborator UNKNOWN

  • Notre-dame Hospital

    collaborator UNKNOWN

  • Ottawa Hospital Research Institute

    collaborator OTHER

  • Alberta Health services

    lead OTHER

Principal Investigators

  • Naresh Jha, MBBS · AHS Cancer Control Alberta

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Completion
2008-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168181 on ClinicalTrials.gov